TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9552221
Drug: Both i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both i.v. methylprednisolone and oral amoxicillin-clavulanic acid as above
Study: 29633349
Drug: Metformin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin treatment (n = 188)
Study: 28443383
Drug: Lactobacillus casei
Normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus casei strain Shirota (LcS) - 100 ml of LcS-fermented milk daily for 8 weeks prior to and 3 weeks after the exam
Study: 28443383
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - non-fermented placebo milk daily for 8 weeks prior to and 3 weeks after the exam
Study: 26311751
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment response
Study: 24045248
Drug: Regimen A
Normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A (craniocaudal scan direction with 120 mL contrast)
Study: 19951554
Drug: L-arginine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine 400 mg group
Study: 2644748
Drug: Atracurium (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (0.1 mg.kg‐1) - up to 8 incremental doses
Study: 729619
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg pseudoephedrine capsules every twelve hours for seven consecutive days
Study: 729619
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg pseudoephedrine capsules every twelve hours for seven consecutive days
Study: 25892145
Drug: Afatinib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib (40 mg/day)
Study: 31501887
Drug: Methotrexate (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (40 mg/m2/week)
Study: 21275922
Drug: Non-OC phase
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-OC phase (hormone-free phase)
Study: 19111408
Drug: ESR2 G‐G‐G
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESR2 G‐G‐G haplotype (major allele for all polymorphisms)
Study: 11455373
Drug: Postoperative ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Postoperative ibuprofen therapy (400 mg taken orally 1 hour before separator placement and a lactose capsule taken orally 6 hours after the initial dose)
Study: 11455373
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of preemptive and postoperative ibuprofen therapy (lactose capsule taken orally 1 hour before separator placement and 400 mg ibuprofen taken 6 hours after the initial placebo)
Study: 11455373
Drug: Lactose capsule
Normalized name: lactose Oral Capsule
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose capsule (control group)
Study: 3053941
Drug: Daflon 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daflon 500 mg (2 tabs daily for 6 weeks)
Study: 18236783
Drug: Buccoadhesive film
Normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccoadhesive film containing 30 mg of ketorolac tromethamine (KT)
Study: 9695137
Drug: Corticotropin-releasing hormone
Normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticotropin-releasing hormone (CRH) 1 microgram/kg
Study: 16287344
Drug: 5.0 g
Normalized name: IODINE 5.0 g in 1 L TOPICAL SOLUTION [FS-104]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 g Cr + 20 g dextrose (Cr)
Study: 30579992
Drug: Laser ablation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser ablation and three times aminolaevulinic acid-based photodynamic therapy (ALA-PDT)
Study: 22759488
Drug: Intravenous regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous regional anaesthesia
Study: 19958629
Drug: rAd‐p53 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: rAd‐p53 injection combined with cisplatin
Study: 26806546
Drug: ViveSoy® (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: ViveSoy® (500 mL per day, 15 g of protein, 50 mg of isoflavones)
Study: 26516121
Drug: LY2495655 (LY)
Normalized name: LYS
DrugBank: Lysine (DB00123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LY2495655 (LY) 315 mg
Study: 16413878
Drug: Iron (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron (12.5 mg) and folic acid (50 microg)
Study: 12794395
Drug: 5.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg/kg rPAF‐AH
Study: 12794395
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg rPAF‐AH
Study: 1850208
Drug: Once-weekly psychotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly psychotherapy, family therapy, or group therapy led by paraprofessionals
Study: 7140566
Drug: Cimetidine (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1,000 mg/d)
Study: 7140566
Drug: Antacids (magnesium-aluminium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacids (magnesium-aluminium hydroxide, neutralization capacity 564 mmol/d)
Study: 31957666
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (300,000 IU intramuscular injection)
Study: 28964736
Drug: Alirocumab 75
Normalized name: alirocumab 75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 75 mg Q2W
Study: 28964736
Drug: Alirocumab 150
Normalized name: alirocumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 150 mg Q2W
Study: 31708410
Drug: Alirocumab dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab dose increase to 150 mg Q2W
Study: 31708410
Drug: Background statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Background statin therapy
Study: 28844193
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with warfarin, P2Y12 inhibitor, and aspirin
Study: 28844193
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy with dabigatran (both doses combined)
Study: 26004431
Drug: Metformin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin treatment (dosage not specified)
Study: 19104789
Drug: Atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10 mg/day for 14 days)
Study: 17076982
Drug: IM haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IM haloperidol 6.5 mg
Study: 10902797
Drug: Leptin levels
Normalized name: leptin
DrugBank: Leptin (DB05098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leptin levels in peritoneal fluid (PF) (35.9 +/- 17.4 ng/mL)
Study: 10902797
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group serum leptin levels (15.6 +/- 8.4 ng/mL)
Study: 10902797
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group PF leptin levels (17.5 +/- 7.2 ng/mL)
Study: 9017127
Drug: Small‐Carrion implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small‐Carrion implants
Study: 29588232
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg slow-release propranolol
Study: 23785525
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with annual mass treatment for three years (3×)
Study: 23785525
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with stopping rule (SR)
Study: 23785525
Drug: Enhanced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment with annual mass treatment for three years (3×)
Study: 23785525
Drug: Enhanced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment with stopping rule (SR)
Study: 23785525
Drug: One round
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One round of mass drug administration (MDA)
Study: 12918544
Drug: Novel antiplatelet
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel antiplatelet and anticoagulant strategies
Study: 12918544
Drug: Novel agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel agents targeting haemostatic pathways
Study: 12918544
Drug: New compounds
Approvals — FDA: no, EMA: no, PMDA: no
Description: New compounds
Study: 8796665
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses (0.075, 0.100, 0.150, 0.200 mmol/kg)
Study: 28114979
Drug: Prolonged antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged antibiotic therapy (15 days)
Study: 26649908
Drug: Epidural ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ropivacaine 0 mg (Control)
Study: 26649908
Drug: Epidural ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ropivacaine 50 mg
Study: 26649908
Drug: Epidural ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ropivacaine 100 mg
Study: 19066345
Drug: Bicarbonate/lactate-based peritoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate/lactate-based peritoneal dialysis solution (P)
Study: 2397543
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) treatment with herbs: Bupleurum chinense, Scutellaria baicalensis, Astragalus membranaceus, Codonopsis pilosula, Ligustrum lucidum, Lophatherum gracile, and thread of ivory, for 1-3 courses of treatment lasting one month each.
Study: 28647684
Drug: Anti-H. pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-H. pylori treatment at baseline
Study: 24600204
Drug: Olmesartan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan (20 mg once daily for 16 weeks)
Study: 24600204
Drug: Candesartan (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (8 mg once daily for 16 weeks)
Study: 24600204
Drug: Telmisartan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (40 mg once daily for 16 weeks)
Study: 22257505
Drug: Inspiratory muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory muscle training using Threshold IMT device (G-1; n = 16)
Study: 22257505
Drug: Biofeedback (G-2;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback (G-2; n = 15)
Study: 11145492
Drug: Venlafaxine 75
Normalized name: venlafaxine 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 75 mg daily
Study: 19963436
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate 100 mg daily
Study: 18295343
Drug: Quetiapine switch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine switch (mean dose=290.0 mg/day, S.D.=55.2)
Study: 18295343
Drug: Risperidone continuation
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone continuation (mean dose=4.1 mg/day, S.D.=1.2)
Study: 11485375
Drug: L-NMMA with
Normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA with BQ-123
Study: 28666463
Drug: Adjunctive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive treatment by homeopaths
Study: 21862001
Drug: Mock TEAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mock TEAS treatment (group I, n = 99)
Study: 21862001
Drug: Single TEAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single TEAS treatment (group II, n = 110)
Study: 17805062
Drug: Sequential Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential Docetaxel (75 mg/m2)
Study: 17805062
Drug: Sequential Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential Docetaxel
Study: 15070418
Drug: Methylphenidate 1
Normalized name: methylphenidate 17.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 1 mg/kg/day + zinc sulfate 55 mg/day (with approximately 15 mg zinc element)
Study: 15070418
Drug: Methylphenidate 1
Normalized name: methylphenidate 17.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 1 mg/kg/day + placebo (sucrose 55 mg)
Study: 12227888
Drug: Triptorelin (Decapeptyl)
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triptorelin (Decapeptyl) and goserelin (Zoladex) - GnRH agonists, 4-month treatment course
Study: 2513206
Drug: Nicardipine 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 80 mg/day
Study: 2513206
Drug: Nifedipine 40
Normalized name: nifedipine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 40 to 80 mg/day
Study: 2513206
Drug: Verapamil 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 320 mg/day
Study: 5303665
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: one dose of 1 ml of cholera El Tor vaccine containing 8 x 10(9) organisms/ml
Study: 5303665
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 2 doses (1 ml each) of cholera El Tor vaccine containing 8 x 10(9) organisms/ml
Study: 5303665
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: one dose of cholera El Tor vaccine containing 16 x 10(9) organisms/ml
Study: 5303665
Drug: Group D:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D: 2 doses of typhoid vaccine
Study: 31221888
Drug: rhinothermy delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhinothermy delivered by nasal high flow therapy (rNHF) at 41°C for 2 hours daily for five days
Study: 23741829
Drug: Lincomycin hydrochloride
Normalized name: Lincomycin Hydrochloride
DrugBank: Lincomycin (DB01627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lincomycin hydrochloride 500 mg capsules
Study: 23741829
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil 200 mg tablets
Study: 7003855
Drug: Diethylcarbamazine (DEC)
Normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylcarbamazine (DEC) lotion, applied daily for seven days, then weekly for seven weeks
Study: 31544378
Drug: Acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture and moxibustion therapy of Tiaochongren Gushenyuan
Study: 29037576
Drug: Maternal vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal vaccination during pregnancy (not specified dosage or duration)
Study: 18285589
Drug: Annual mass
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual mass azithromycin administration
Study: 16355608
Drug: Changji' an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changji' an (CJA) oral liquid
Study: 12804182
Drug: ATG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG treatment for GVHD prophylaxis
Study: 12804182
Drug: No ATG
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ATG treatment for GVHD prophylaxis
Study: 10588209
Drug: 50-mg bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50-mg bolus of recombinant tissue-type plasminogen activator (rt-PA)
Study: 8475268
Drug: Uniphasic injection
Normalized name: insulin isophane, pork / insulin, regular, pork Injectable Suspension [Hypurin Porcine Biphasic Isophane]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uniphasic injection protocol
Study: 3515925
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of intramuscular morphine sulfate
Study: 31564356
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injection on a monthly basis for 3 months, followed by bimonthly injections for another 9 months.
Study: 25595177
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injection
Study: 24777811
Drug: Control (Atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Atorvastatin 10 mg during run-in period)
Study: 24659566
Drug: Clarithromycin 250
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 250 mg/day for 12 weeks
Study: 24659566
Drug: Clarithromycin 250
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 250 mg/day for 24 weeks
Study: 17908130
Drug: Complex intervention
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex intervention with treatment fidelity procedures (specific details on dosage and duration not available)
Study: 17908130
Drug: Treatment fidelity
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment fidelity procedures applied in the SPHERE study
Study: 17908130
Drug: Behavior Change
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior Change Consortium's model of treatment fidelity
Study: 14684407
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral doses of 100 mg elemental Fe and 500 micro g folic acid
Study: 14684407
Drug: 3 intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 intramuscular doses of 250 mg elemental Fe as iron dextran at 1‐mo intervals and oral doses of 5 mg folic acid twice weekly
Study: 6121479
Drug: Intravenous atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous atenolol (5 to 15 mg)
Study: 19238808
Drug: Caffeine, 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine, 600 mg (n=12)
Study: 19238808
Drug: Modafinil, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil, 400 mg (n=12)
Study: 11607890
Drug: Transdermal oestradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal oestradiol + vaginal progesterone (Group 2)
Study: 11607890
Drug: Oral oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oestradiol + vaginal progesterone (Group 3)
Study: 11607890
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without therapy (Group 4)
Study: 8032838
Drug: Clean intermittent
Normalized name: Noxzema Clean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clean intermittent catheterization (CIC) weekly for 1 year
Study: 1922166
Drug: L-carnitine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (1 g/orally b.i.d.)
Study: 6763836
Drug: Behavioural treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural treatment programme
Study: 6763836
Drug: Cardiological measures
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiological measures (e.g. diet, exercise, adherence to medication)
Study: 31302644
Drug: Sham opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham opioid infusion (saline solution)
Study: 25720388
Drug: Subcutaneous exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous exenatide for 11 days
Study: 19809230
Drug: Subacromial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subacromial injection of 9 ml bupivacaine and 1 ml betamethasone
Study: 17520986
Drug: Intranasal sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal sufentanil (2 microg/kg)
Study: 17520986
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (0.5 mg/kg in cherry juice)
Study: 17520986
Drug: Oral tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tramadol (3 mg/kg drops)
Study: 15567986
Drug: Recombinant HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant HBV vaccine (20 microg doses at months 0, 1, and 6)
Study: 12368393
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g FOS + 80 mg cornstarch
Study: 12368393
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g sucrose + 80 mg cornstarch
Study: 7985753
Drug: Malaria sporozoite
Normalized name: Plasmodium malariae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malaria sporozoite vaccine (R32NS1(81))
Study: 30926654
Drug: Gastric cancer
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric cancer risk prediction rule (based on age, sex, PG I/II ratio, G-17 level, H. pylori infection, pickled food, fried food)
Study: 25188398
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) control condition over 4 months
Study: 11234653
Drug: Multivitamin-mineral combination
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin-mineral combination (Berocca Calmag)
Study: 31870634
Drug: Liraglutide 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 1.8 mg daily for 26 weeks
Study: 26738641
Drug: Motivational enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational enhancement therapy (MET) and strengths-based case management (SBCM)
Study: 31634025
Drug: IIV4-HD by
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIV4-HD by subcutaneous injection
Study: 31634025
Drug: IIV4-SD by
Normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIV4-SD by subcutaneous injection
Study: 31634025
Drug: IIV4-HD by
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIV4-HD by intramuscular injection
Study: 27664002
Drug: Stop/reduce vasoactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stop/reduce vasoactive therapy
Study: 27664002
Drug: Continue vasoactive
Normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue vasoactive therapy
Study: 19682111
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment (higher-dose)
Study: 9829367
Drug: AO-128 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: AO-128 (2 mg three times daily)